A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4. Singh D, Guller P, Reid F, Doffman S, et al. Eur Respir J 2025;66:2402231.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Singh D, Guller P, Reid F, Doffman S, et al. A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4. Eur Respir J 2025;66:2402231.
PMID: 40154559